



Exercise of options and PDMR dealing

February 29, 2024 9:21 AM EST

RNS Number : 9585E
MaxCyte, Inc.
29 February 2024



MaxCyte, Inc.

("MaxCyte" or the "Company")

Exercise of options and PDMR dealing

ROCKVILLE, MD, February 29, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 26 February 2024, as per a filing lodged with the U.S. Securities and Exchange Commission, John Johnston, a Non-Executive Director of the Company, exercised options over 5,000 shares of common stock of \$0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 5,000 new shares of Common Stock were issued pursuant to the Company's existing its block admission facility and were sold by John Johnston at a price range between \$4.510 and \$4.625 per Common Stock ("Sale"). The sold shares represent approximately 1.7% of John Johnston's total equity and option holdings in the Company's stock capital, respectively.

Following the Exercise and Sale, John Johnston holds 120,583 shares of Common Stock representing 0.1% of the issued stock capital of the Company. Following the Exercise, John Johnston holds a further 167,217 options over Common Stock.

The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by John Johnston on 28 March 2023 relating solely to the sale of shares acquired from exercise of options that expire on 4 March 2029.

MaxCyte Contacts:

US IR Adviser

Gilmartin Group
David Deuchler, CFA

+1 415-937-5400
ir@maxcyte.com

Nominated Adviser and Joint Corporate Broker

Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden

+44 (0)20 7886 2500

UK IR Adviser
ICR Consilium
 Mary-Jane Elliott
 Chris Welsh

+44 (0)203 709 5700
maxcyte@consilium-comms.com

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on [Twitter](https://twitter.com/maxcyte) and [LinkedIn](https://www.linkedin.com/company/maxcyte).

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated					
a)	Name	John Johnston				
2	Reason for the notification					
a)	Position/status	Non-Executive Director				
b)	Initial notification /Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	MaxCyte, Inc.				
b)	LEI	54930053YHXULRFCU991				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument Identification code	Common Stock of \$0.01 each US57777K1060				
b)	Nature of the transaction	Exercise of Options over common stock				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Exercise Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>\$2.142</td> <td>5,000</td> </tr> </tbody> </table>	Exercise Price(s)	Volume(s)	\$2.142	5,000
Exercise Price(s)	Volume(s)					
\$2.142	5,000					

d)	Aggregated information - Aggregated volume - Price	5,000 \$2.142
e)	Date of the transaction	26 February 2024
f)	Place of the transaction	US Stock Exchange, Nasdaq

1	Details of the person discharging managerial responsibilities / person closely associated															
a)	Name	John Johnston														
2	Reason for the notification															
a)	Position/status	Non-Executive Director														
b)	Initial notification /Amendment	Initial notification														
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor															
a)	Name	MaxCyte, Inc.														
b)	LEI	54930053YHXULRFCU991														
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted															
a)	Description of the financial instrument, type of instrument Identification code	Common Stock of \$0.01 each US57777K1060														
b)	Nature of the transaction	Sale of common stock														
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Exercise Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>\$4.5100</td> <td>100</td> </tr> <tr> <td>\$4.5700</td> <td>432</td> </tr> <tr> <td>\$4.5800</td> <td>12</td> </tr> <tr> <td>\$4.5900</td> <td>896</td> </tr> <tr> <td>\$4.5925</td> <td>63</td> </tr> <tr> <td>\$4.5950</td> <td>467</td> </tr> </tbody> </table>	Exercise Price(s)	Volume(s)	\$4.5100	100	\$4.5700	432	\$4.5800	12	\$4.5900	896	\$4.5925	63	\$4.5950	467
Exercise Price(s)	Volume(s)															
\$4.5100	100															
\$4.5700	432															
\$4.5800	12															
\$4.5900	896															
\$4.5925	63															
\$4.5950	467															

		<table border="1"> <tr> <td>\$4.6000</td> <td>901</td> </tr> <tr> <td>\$4.6050</td> <td>180</td> </tr> <tr> <td>\$4.6100</td> <td>620</td> </tr> <tr> <td>\$4.6150</td> <td>226</td> </tr> <tr> <td>\$4.6200</td> <td>366</td> </tr> <tr> <td>\$4.6250</td> <td>737</td> </tr> <tr> <td></td> <td></td> </tr> </table>	\$4.6000	901	\$4.6050	180	\$4.6100	620	\$4.6150	226	\$4.6200	366	\$4.6250	737		
\$4.6000	901															
\$4.6050	180															
\$4.6100	620															
\$4.6150	226															
\$4.6200	366															
\$4.6250	737															
d)	Aggregated information - Aggregated volume - Price	5,000 \$4.6005														
e)	Date of the transaction	26 February 2024														
f)	Place of the transaction	US Stock Exchange, Nasdaq														

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHEANANAAELEEA